W. Thomas Purcell

2.5k total citations
40 papers, 935 citations indexed

About

W. Thomas Purcell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, W. Thomas Purcell has authored 40 papers receiving a total of 935 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in W. Thomas Purcell's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (6 papers) and Cancer survivorship and care (6 papers). W. Thomas Purcell is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (6 papers) and Cancer survivorship and care (6 papers). W. Thomas Purcell collaborates with scholars based in United States, Australia and Hong Kong. W. Thomas Purcell's co-authors include David S. Ettinger, D. Ross Camidge, Robert C. Doebele, Dara L. Aisner, Paul A. Bunn, Anh T. Le, Tejas Patil, Manuel Hidalgo, Michelle A. Rudek and Derek Smith and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

W. Thomas Purcell

36 papers receiving 919 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Thomas Purcell United States 16 534 518 244 184 95 40 935
Francesca Mazzoni Italy 18 568 1.1× 470 0.9× 178 0.7× 160 0.9× 67 0.7× 63 821
Toshio Fujino Japan 16 420 0.8× 563 1.1× 402 1.6× 142 0.8× 98 1.0× 54 975
Im Il Na South Korea 14 508 1.0× 568 1.1× 233 1.0× 125 0.7× 73 0.8× 38 911
Fumiyoshi Ohyanagi Japan 20 561 1.1× 673 1.3× 263 1.1× 199 1.1× 203 2.1× 68 1.1k
Rosario García‐Campelo Spain 19 808 1.5× 817 1.6× 468 1.9× 274 1.5× 92 1.0× 47 1.5k
Erin Larkins United States 14 637 1.2× 441 0.9× 286 1.2× 162 0.9× 41 0.4× 28 937
Federica Biello Italy 20 634 1.2× 418 0.8× 267 1.1× 292 1.6× 62 0.7× 56 994
Youngjoo Lee South Korea 17 583 1.1× 472 0.9× 256 1.0× 243 1.3× 182 1.9× 78 939
Ramon Andrade de Mello Portugal 21 745 1.4× 565 1.1× 477 2.0× 314 1.7× 145 1.5× 89 1.4k
Chia‐Chi Lin Taiwan 15 356 0.7× 340 0.7× 297 1.2× 106 0.6× 108 1.1× 44 835

Countries citing papers authored by W. Thomas Purcell

Since Specialization
Citations

This map shows the geographic impact of W. Thomas Purcell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Thomas Purcell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Thomas Purcell more than expected).

Fields of papers citing papers by W. Thomas Purcell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Thomas Purcell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Thomas Purcell. The network helps show where W. Thomas Purcell may publish in the future.

Co-authorship network of co-authors of W. Thomas Purcell

This figure shows the co-authorship network connecting the top 25 collaborators of W. Thomas Purcell. A scholar is included among the top collaborators of W. Thomas Purcell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Thomas Purcell. W. Thomas Purcell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davis, S. Lindsey, Wells A. Messersmith, W. Thomas Purcell, et al.. (2024). A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors. Cancers. 16(8). 1456–1456.
2.
Kittelson, Andrew J., et al.. (2022). Development of a Reference Chart for Monitoring Cancer-Related Fatigue Throughout a Supervised Exercise Program. Rehabilitation Oncology. 40(2). 82–88. 4 indexed citations
3.
Martin, Emily C., et al.. (2021). Psychotropic medications in oncology. Supportive Care in Cancer. 29(11). 6801–6806. 2 indexed citations
4.
Gerson, Stanton L., Kate Shaw, Louis B. Harrison, et al.. (2021). Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers. Journal of the National Comprehensive Cancer Network. 19(6). 726–732. 3 indexed citations
5.
Peters, John C., et al.. (2020). Single-Leg Stance Times in a Diverse Group of Survivors of Cancer and the Relationship to History of Recent Falls. Rehabilitation Oncology. 39(1). 23–30. 7 indexed citations
6.
Patil, Tejas, Jose M. Pacheco, Anastasios Dimou, et al.. (2020). Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology. 10. 510–510. 1 indexed citations
7.
McCoach, Caroline E., Collin M. Blakely, Kimberly C. Banks, et al.. (2018). Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(12). 2758–2770. 114 indexed citations
8.
9.
Dewberry, Lindel C., Ashley E. Glode, Tracey E. Schefter, et al.. (2018). Pilot Prehabilitation Program for Patients With Esophageal Cancer During Neoadjuvant Therapy and Surgery. Journal of Surgical Research. 235. 66–72. 32 indexed citations
10.
Patil, Tejas, Derek Smith, Paul A. Bunn, et al.. (2018). The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology. 13(11). 1717–1726. 138 indexed citations
11.
Patil, Tejas, Danielle Smith, Paul A. Bunn, et al.. (2018). P1.01-78 The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib. Journal of Thoracic Oncology. 13(10). S492–S493.
12.
Heist, Rebecca S., Michael J. Guarino, Gregory A. Masters, et al.. (2017). Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Journal of Clinical Oncology. 35(24). 2790–2797. 139 indexed citations
13.
Noonan, Sinéad, Tejas Patil, Dexiang Gao, et al.. (2017). Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. Journal of Thoracic Oncology. 13(1). 134–138. 19 indexed citations
14.
Robin, Tyler P., D. Ross Camidge, Kelly Stuhr, et al.. (2017). Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(5). 715–720. 39 indexed citations
15.
16.
Rudek, Michelle A., Arvind Dasari, Daniel A. Laheru, et al.. (2015). Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. The Journal of Clinical Pharmacology. 56(8). 966–973. 11 indexed citations
17.
Purcell, W. Thomas, et al.. (2014). One institution's experience with implementation of EPIC/Beacon: lessons learned.. PubMed. 28(2). 105–6, 108, C3. 4 indexed citations
18.
Purcell, W. Thomas & David S. Ettinger. (2003). Novel antifolate drugs. Current Oncology Reports. 5(2). 114–125. 85 indexed citations
19.
Purcell, W. Thomas, Michelle A. Rudek, & Manuel Hidalgo. (2002). Development of matrix metalloproteinase inhibitors in cancer therapy. Hematology/Oncology Clinics of North America. 16(5). 1189–1227. 44 indexed citations
20.
Purcell, W. Thomas & Ross C. Donehower. (2002). Evolving therapies: Farnesyltransferase inhibitors. Current Oncology Reports. 4(1). 29–36. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Mazzoni Breakdown of academic impact, for papers by Toshio Fujino Breakdown of academic impact, for papers by Im Il Na Breakdown of academic impact, for papers by Fumiyoshi Ohyanagi Breakdown of academic impact, for papers by Rosario García‐Campelo Breakdown of academic impact, for papers by Erin Larkins Breakdown of academic impact, for papers by Federica Biello Breakdown of academic impact, for papers by Youngjoo Lee Breakdown of academic impact, for papers by Ramon Andrade de Mello Breakdown of academic impact, for papers by Chia‐Chi Lin
Rankless by CCL
2026